SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (AMEX:BSM) today announced that Rolf Issels, MD, PhD gave the keynote lecture at the biannual meeting of the German Cancer Society held February 20-24, 2008 using as his subject the clinical application of hyperthermia therapy in treating cancer. The lecture, entitled “Heat Is on in Oncology,” received a standing ovation from the 400 people in attendance. Dr. Michael Bamburg, President of the German Cancer Society, stated in his opening remarks that the German Cancer Society had chosen hyperthermia therapy as the subject of this keynote lecture to draw attention to the recent milestone in the field of hyperthermic oncology achieved by the EORTC/ESHO soft tissue sarcoma trial under the leadership of Dr. Issels. This phase 3 study involving 341 patients showed an approximate doubling of local progression-free survival and disease-free survival for patients who received hyperthermia therapy and chemotherapy, as opposed to those who received chemotherapy alone. All hyperthermia treatments were given using the BSD-2000 by BSD Medical Corporation.
